ArticleFrontiers in immunology2026
Evaluation of primate anti-pig xenoreactive immune responses using immortalized aortic endothelial cells from genetically modified pigs.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine vascular endothelial cells are primary targets of humoral and cellular immune responses in pig-to-primate organ xenotransplantation. Although porcine aortic endothelial cells (PAECs) are widely used to evaluate primate anti-pig immune responses, their limited proliferative capacity poses a significant obstacle to repeated and standardized experimentation. To overcome this challenge, we established immortalized PAEC lines (iPAECs) derived from WT, GTKO, and GTKO/CMAHKO/B4GALNT2KO (triple-knockout, TKO) donor pigs using stable transduction of the SV40 large T antigen. All iPAEC lines expanded stably beyond passage 20, maintained high CD31 expression, and preserved genotype-specific xenoantigen profiles. Anti-pig IgM/IgG binding and complement-dependent cytotoxicity (CDC) against these cells were measured with flow cytometry using pooled rhesus monkey sera (n=20) or human sera (n=20). Compared with WT iPAECs, GTKO iPAECs demonstrated significantly reduced IgM/IgG binding and CDC with human and rhesus sera. Additional deletion of Sda and Neu5Gc in TKO iPAECs markedly reduced human serum reactivity, whereas rhesus sera retained relatively high antibody binding and CDC against TKO iPAECs. Notably, the humoral immune responses remained consistent across primary cells and passages P5, P10, and P20, validating the long-term efficacy of iPAECs as an experimental tool. Preformed anti-pig antibodies in 30 rhesus monkeys were further evaluated using TKO iPAECs and TKO peripheral blood mononuclear cells (PBMCs). The results demonstrated a significant correlation between the two target cell types, supporting their interchangeability for humoral immune assessment. Furthermore, xenogeneic MLR assays confirmed that iPAECs could stimulate human CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.